AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy

Recruitingn/aAges 18 Years - 70 YearsAllyuanli Zhao
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * (1) 18 to 70 years of age * (2) Diagnosed with a single cerebral cavernous malformation * (3) No prior treatment of the symptomatic lesion Exclusion Criteria: * (1) Associated with brain lesions and/or tumors other than CCM * (2) History of previous intracranial surgery * (3) Prior brain irradiation * (4) Contraindication or unwilling or unable to undergo research MRI studies * (5) Pregnant or breastfeeding women * (6) Persons unable or unlikely to return for follow-up visits * (7) Dementia or other progressive neurological disease
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

2 sites
Beijing Tiantan Hospital, Capital Medical University
Beijing, China
Peking University International Hospital
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy